Pharmacological efficacy of anti-IL-1β scFv, Fab and full-length antibodies in treatment of rheumatoid arthritis

Molecular Immunology

Volumn 57, Issue 2, 2014, Pages 59-65

  Qi, Jianying ^a   Ye, Xianlong ^a   Ren, Guiping ^a   Kan, Fangming ^a   Zhang, Yu ^a   Guo, Mo ^a   Zhang, Zhiyi ^b   Li, Deshan ^a  

^a NORTHEAST AGRICULTURAL UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Fab; Full length antibody; Interleukin 1 (IL 1 ); Rheumatoid arthritis (RA); Single chain Fv (scFv)

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN F(AB) FRAGMENT; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA ANTIBODY; INTERLEUKIN 1BETA ANTIBODY IMMUNOGLOBULIN F(AB) FRAGMENT; INTERLEUKIN 1BETA ANTIBODY SINGLE CHAIN FRAGMENT VARIANT; INTERLEUKIN 1BETA FULL LENGTH ANTIBODY; INTERLEUKIN 2; INTERLEUKIN 6; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DOWN REGULATION; EX VIVO STUDY; HUMORAL IMMUNITY; IMMUNOTHERAPY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; THERAPY EFFECT;

FAB; FULL-LENGTH ANTIBODY; INTERLEUKIN-1Β (IL-1Β); RHEUMATOID ARTHRITIS (RA); SINGLE-CHAIN FV (SCFV);

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CELL PROLIFERATION; IMMUNOGLOBULIN FAB FRAGMENTS; INFLAMMATION; INTERFERON-GAMMA; INTERLEUKIN-1BETA; INTERLEUKIN-2; INTERLEUKIN-6; MALE; MATRIX METALLOPROTEINASE 3; MICE; SINGLE-CHAIN ANTIBODIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84884918992     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2013.08.002     Document Type: Article

References (41)

1. Andersen D.C., Reilly D.E. Production technologies for monoclonal antibodies and their fragments. Curr. Opin. Biotechnol. 2004, 15(5):456-462. (PubMed: 15464378).
2. Andreakos E., Taylor P.C., Feldmann M. Monoclonal antibodies in immune and inflammatory diseases. Curr. Opin. Biotechnol. 2002, 13:615-620. (PubMed: 12482523).
3. Arbabi-Ghahroudi M., Tanha J., MacKenzie R. Prokaryotic expression of antibodies. Cancer Metastasis Rev. 2005, 24(4):501-519. (PubMed: 16408159).
4. Aricescu A.R., Assenberg R., Bill R.M., Busso D., Chang V.T., Davis S.J., Dubrovsky A., Gustafsson L., Hedfalk K., Heinemann U., Jones I.M., Ksiazek D., Lang C., Maskos K., Messerschmidt A., Macieira S., Peleg Y., Perrakis A., Poterszman A., Schneider G., Sixma T.K., Sussman J.L., Sutton G., Tarboureich N., Zeev-Ben-Mordehai T., Jones E.Y. Eukaryotic expression: developments for structural proteomics. Acta Crystallogr. D: Biol. Crystallogr. 2006, 62(Pt 10):1114-1124. (PubMed: 17001089).
5. Batra S.K., Jain M., Wittel U.A., Chauhan S.C., Colcher D. Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr. Opin. Biotechnol. 2002, 13:603-608. (PubMed: 12482521).
6. Bird R.E., Hardman K.D., Jacobson J.W., Johnson S., Kaufman B.M., Lee S.M., Lee T., Pope S.H., Riordan G.S., Whitlow M. Single-chain antigen-binding proteins. Science 1988, 242(4877):423-426. (PubMed: 3140379).
7. Borrebaecka C.A., Carlssonb R. Human therapeutic antibodies. Curr. Opin. Pharmacol. 2001, 1:404-408.
8. Brand D.D., Latham K.A., Rosloniec E.F. Collagen-induced arthritis. Nat. Protoc. 2007, 2(5):1269-1275. (PubMed: 17546023).
9. Choi E.M., Kim Y.H. A preliminary study of the effects of an extract of Ligularia fischeri leaves on type II collagen-induced arthritis in DBA/1J mice. Food Chem. Toxicol. 2008, 46(1):375-379. (PubMed: 17904263).
10. Feldmann M., Brennan F.M., Williams R.O., Cope A.P., Gibbons D.L., Katsikis P.D., Maini R.N. Evaluation of the role of cytokines in autoimmune disease: the importance of TNF alpha in rheumatoid arthritis. Prog. Growth Factor Res. 1992, 4(3):247-255. (PubMed: 1307491).
11. Feldmann M., Brennan F.M., Maini R.N. Rheumatoid arthritis. Cell 1996, 85(3):307-310.
12. Holt I., Cooper R.G., Denton J., Meager A., Hopkins S.J. Cytokine inter-relationships and their association with disease activity in arthritis. Rheumatology 1992, 31(11):725-733. (PubMed: 1304740).
13. Humphreys D.P., Glover D.J. Therapeutic antibody production technologies: molecules, applications, expression and purification. Curr. Opin. Drug Discov. Dev. 2001, 4(2):172-185. (PubMed: 11378956).
14. Jiang X., Ookubo Y., Fujii I., Nakano H., Yamane T. Expression of Fab fragment of catalytic antibody 6D9 in an Escherichia coli in vitro coupled transcription/translation system. FEBS Lett. 2002, 514:290-294. (PubMed: 11943168).
15. Juárez-González V.R., Riaño-Umbarila L., Quintero-Hernández V., Olamendi-Portugal T., Ortiz-León M., Ortíz E., Possani L.D., Becerril B. Directed evolution, phage display and combination of evolved mutants: a strategy to recover the neutralization properties of the scFv version of BCF2 a neutralizing monoclonal antibody specific to scorpion toxin Cn2. J. Mol. Biol. 2005, 346(5):1287-1297. (PubMed: 15713481).
16. Kahle P., Saal J.G., Schaudt K., Zacher J., Fritz P., Pawelec G. Determination of cytokines in synovial fluids: correlation with diagnosis and histomorphological characteristics of synovial tissue. Ann. Rheum. Dis. 1992, 51:731-734. (PubMed: 1004735).
17. Lettesjö H., Nordström E., Ström H., Nilsson B., Glinghammar B., Dahlstedt L., Möller E. Synovial fluid cytokines in patients with rheumatoid arthritis or other arthritic lesions. Scand. J. Immunol. 1998, 48(3):286-292. (PubMed: 9743215).
18. Leung S., Liu X., Fang L., Chen X., Guo T., Zhang J. The cytokine milieu in the interplay of pathogenic Th1/Th17 cells and regulatory T cells in autoimmune disease. Cell. Mol. Immunol. 2010, 7(3):182-189. (PubMed: 20383174).
19. McCafferty J., Griffiths A.D., Winter G., Chiswell D.J. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990, 348(6301):552-554. (PubMed: 2247164).
20. Miyashita H., Hara T., Tanimura R., Fukuyama S., Cagnon C., Kohara A., Fujii I. Site-directed mutagenesis of active site contact residues in a hydrolytic abzyme: evidence for an essential histidine involved in transition state stabilization. J. Mol. Biol. 1997, 267(5):1247-1257. (PubMed: 9150409).
21. Morino K., Katsumi H., Akahori Y., Iba Y., Shinohara M., Ukai Y., Kohara Y., Kurosawa Y. Antibody fusions with fluorescent proteins: a versatile reagent for profiling protein expression. J. Immunol. Methods 2001, 257(1-2):175-184. (PubMed:11687251).
22. Neuberger M.S., Williams G.T., Fox R.O. Recombinant antibodies possessing novel effector functions. Nature 1984, 312(5995):604-608. (PubMed:2513468).
23. Neuberger M.S., Williams G.T., Mitchell E.B., Jouhal S.S., Flanagan J.G., Rabbitts T.H. A hapten-specific chimaeric IgE antibody with human physiological effector function. Nature 1985, 314(6008):268-270. (PubMed: 2580239).
24. Proba K., Riesenberg D. Producing antibodies in Escherichia coli: From PCR to fermentation. Antibody Engineering, 1996, 203-252. IRL Press, Oxford. J. McCafferty, H.R. Hoogenboom, D.J. Chiswell (Eds.).
25. Qi J.Y., Kan F.M., Ye X.L., Guo M., Zhang Y., Ren G.P., Li D.S. A bispecific antibody against IL-1β and IL-17A is beneficial for experimental rheumatoid arthritis. Int. Immunopharmacol. 2012, 14(4):770-778. (PubMed: 23092552).
26. Quintero-Hernández V., Juárez-González V.R., Ortíz-León M., Sánchez R., Possani L.D., Becerril B. The change of the scFv into the Fab format improves the stability and in vivo toxin neutralization capacity of recombinant antibodies. Mol. Immunol. 2007, 44(6):1307-1315. (PubMed: 16814388).
27. Raza K., Falciani F., Curnow S.J., Ross E.J., Lee C.Y., Akbar A.N., Lord J.M., Gordon C., Buckley C.D., Salmon M. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res. Ther. 2005, 7(4):R784-R795. (PubMed: 1175027).
28. Rodriguez-Carmona E., Cano-Garrido O., Dragosits M., Maurer M., Mader A., Kunert R., Mattanovich D., Villaverde A., Vázquez F. Recombinant Fab expression and secretion in Escherichia coli continuous culture at medium cell densities: Influence of temperature. Process Biochem. 2012, 47:446-452.
29. Röthlisberger D., Honegger A., Plückthun A. Domain interactions in the Fab fragment: a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability. J. Mol. Biol. 2005, 347:773-789. (PubMed: 15769469).
30. Seo S.K., Choi J.H., Kim Y.H., Kang W.J., Park H.Y., Suh J.H., Choi B.K., Vinay D.S., Kwon B.S. 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat. Med. 2004, 10(10):1088-1094. (PubMed: 15448685).
31. Siegel R.W., Allen B., Pavlik P., Marks J.D., Bradbury A. Mass spectral analysis of a protein complex using single-chain antibodies selected on a peptide target: applications to functional genomics. J. Mol. Biol. 2000, 302(2):285-293. (PubMed: 10970733).
32. Svensson L., Jirholt J., Holmdahl R., Jansson L. B cell-deficient mice do not develop type II collagen-induced arthritis (CIA). Clin. Exp. Immunol. 1998, 111(3):521-526. (PubMed: 9528892).
33. Trikha M., Yan L., Nakada M.T. Monoclonal antibodies as therapeutics in oncology. Curr. Opin. Biotechnol. 2002, 13(6):609-614. (PubMed: 12482522).
34. Watts R.A., Isaacs J.D. Immunotherapy of rheumatoid arthritis. Ann. Rheum. Dis. 1992, 51(5):577-579. (PubMed: 1005683).
35. Weaver A.L. The impact of new biologicals in the treatment of rheumatoid arthritis. Rheumatology 2004, 43(3). iii17-iii23.
36. Weiner L.M., Carter P. The rollercoaster ride to anti-cancer antibodies. Nat. Biotechnol. 2003, 21:510-511. (PubMed: 12721576).
37. Weir A.N., Nesbitt A., Chapman A.P., Popplewell A.G., Antoniw P., Lawson A.D. Formatting antibody fragments to mediate specific therapeutic functions. Biochem. Soc. Trans. 2002, 30(4):512-516. (PubMed: 12196125).
38. Willems A., Leoen J., Schoonooghe S., Grooten J., Mertens N. Optimizing expression and purification from cell culture medium of trispecific recombinant antibody derivatives. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2003, 786(1-2):161-176. (PubMed: 12651012).
39. Williams R.O. Collagen-induced arthritis in mice: a major role for tumor necrosis factor-alpha. Methods Mol. Biol. 2007, 361:265-284. (PubMed: 17172717).
40. Winter G., Milstein C. Man-made antibodies. Nature 1991, 349:293-299. (PubMed: 1987490).
41. Wlad H., Ballagi A., Bouakaz L., Gu Z., Janson J.C. Rapid two-step purification of a recombinant mouse Fab fragment expressed in Escherichia coli. Protein Expr. Purif. 2001, 22(2):325-329. (PubMed: 11437609).